Most of the big pharma players have been working during the past years to implement projects linked to serialisation, despite the uncertainty regarding concrete rules, data and specific regulations. Marga Romo of Nekicessa discusses China: the next deadline for serialisation in China is 2015, with the well-known 128C code, different from the expected data matrix that is likely to be implemented in Europe; and this code is becoming a nightmare for the serialisation-responsible people in the companies, due to technical problems related to length and grading.
https://international-pharma.com/wp-content/uploads/2014/12/Serialisation.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
Serialisation: The Great Challenge for the Pharmaceutical Industry – Considerations on China
